Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.
Please read the tutorial at this link. https://ebooknice.com/page/post?id=faq
We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.
For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.
EbookNice Team
Status:
Available0.0
0 reviewsCONTEXT AND SIGNIFICANCE Autosomal recessive deafness 9 (DFNB9), caused by OTOF gene mutations, is a common form of auditory neuropathy. Clinical trials have demonstrated the efficacy of gene therapy in restoring hearing in DFNB9 patients. However, understanding the auditory recovery process following treatment is critical for optimizing clinical assessments. This study systematically evaluates pre-treatment factors influencing therapeutic outcomes and characterizes post-treatment auditory changes using measures such as auditory brain stem response (ABR), auditory steady-state response (ASSR), and pure-tone audiometry (PTA). The findings reveal progressive improvements in neural auditory responses over time, with significant enhancements in ABR wave latency and amplitude. These insights contribute to a deeper understanding of the mechanisms underlying auditory restoration and provide a framework for refining clinical auditory assessments. SUMMARYBackground: Gene therapy shows promising potential for patients with autosomal recessive deafness 9 (DFNB9), with ongoing clinical trials (ChiCTR2200063181). A deeper understanding of changes in audiological characteristics is crucial for optimizing the monitoring and evaluation of patients’ recovery post-treatment.Methods: Audiological data were collected from 10 DFNB9 patients who underwent gene therapy, including auditory brain stem response (ABR), auditory steady-state response (ASSR), distortion product otoacoustic emission (DPOAE), and pure-tone audiometry (PTA) tests.